Aquestive Therapeutics (AQST) Change in Account Payables (2020 - 2026)
Aquestive Therapeutics (AQST) posted quarterly Change in Account Payables of -$18.0 million for Q1 2026, down 1043.46% year-over-year from $1.9 million in Q1 2025, and down 193.38% quarter-over-quarter from $19.2 million in Q4 2025.
Aquestive Therapeutics (AQST) Change in Account Payables (2020 - 2026) Analysis & Trends
Aquestive Therapeutics' Change in Account Payables history runs 7 years deep, the most recent figure standing at -$18.0 million for Q1 2026.
- In Q1 2026, Change in Account Payables fell 1043.46% year-over-year to -$18.0 million; the TTM figure through Mar 2026 stood at -$355000.0 (down 110.43% YoY), while the FY2025 annual figure was $19.5 million, up 601.76% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$18.0 million, down from $19.2 million in the prior quarter.
- The five-year high for Change in Account Payables was $19.2 million in Q4 2025, with the low at -$18.0 million in Q1 2026.
- The 5-year median for Change in Account Payables is $182000.0 (2022), against an average of $290882.4.
- The sharpest annual moves came in 2023 and 2026: Change in Account Payables surged 1270.33% in 2023, then sank 1043.46% in 2026.
- Aquestive Therapeutics' Change in Account Payables stood at -$1.1 million in 2022, then rose by 5.07% to -$1.1 million in 2023, then jumped by 346.82% to $2.6 million in 2024, then soared by 630.16% to $19.2 million in 2025, then slumped by 193.38% to -$18.0 million in 2026.
- Business Quant data shows AQST's Change in Account Payables at -$18.0 million in Q1 2026, $19.2 million in Q4 2025, and -$1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -53.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -143.74 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -21.20 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Aquestive Therapeutics | 560.60 Mn | 560.60 Mn | 9.80 Mn | -3.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.43 Mn |
| Jun 30, 2026 | -3.43 Mn |
| Mar 31, 2026 | -17.97 Mn |
| Mar 31, 2026 | -17.97 Mn |
| Dec 31, 2025 | 19.25 Mn |
| Dec 31, 2025 | 19.25 Mn |
| Sep 30, 2025 | -1.31 Mn |
| Sep 30, 2025 | -1.31 Mn |
| Jun 30, 2025 | -323,000.00 |
| Jun 30, 2025 | -323,000.00 |
| Mar 31, 2025 | 1.91 Mn |
| Mar 31, 2025 | 1.91 Mn |
| Dec 31, 2024 | 2.64 Mn |
| Dec 31, 2024 | 2.64 Mn |
| Sep 30, 2024 | 1.88 Mn |
| Sep 30, 2024 | 1.88 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Mar 31, 2024 | 1.28 Mn |
| Mar 31, 2024 | 1.28 Mn |